Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in november 2010 in Hamburg, Germany

Eurosurveillance

Volumn 17, Issue 2, 2012, Pages

  Cramer, J P ^a,b   Mac, T ^a   Hogan, B ^b   Stauga, S ^a   Eberhardt, S ^a   Wichmann, O ^c   Mertens, T ^d   Burchard, G D ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; GERMANY; HEMAGGLUTINATION INHIBITION TEST; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H1N1 PDM09; MALE; PANDEMIC INFLUENZA; QUESTIONNAIRE; RISK FACTOR; SEASONAL INFLUENZA; SEROPREVALENCE;

EID: 84856012440     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362(18):1708-19.
2. Robert Koch Institute. Impfung gegen die Neue Influenza A (H1N1). [Vaccination against the New Influena A (H1N1)]. Epidemiologisches Bulletin 41/2009. German. Available from: http://www.rki.de/cln_169/nn_1378492/DE/Content/Infekt/EpidBull/Archiv/2009/41__09,templateId=raw,property=publicationFile.pdf/41_09.pdf
3. Georgette NT. Predicting the herd immunity threshold during an outbreak: a recursive approach. PLoS One. 2009;4(1):e4168.
4. Schmidt F, Tempel G. Repra¨sentative telefonische Erhebung zur Impfung gegen die pandemische Influenza (H1N1) 2009. [Representative telephone survey on vaccination coverage against pandemic influenza (H1N1) 2009. Epidemiologisches Bulletin 25/2010. German. Available from: http://www.rki.de/cln_226/nn_1759378/DE/Content/Infekt/EpidBull/Archiv/2010/25__10,templateId=raw,property=publicationFile.pdf/25_10.pdf
5. Walter D, Bo¨hmer MM, Heiden M, Reiter S, Krause G, Wichmann O. Monitoring pandemic influenza A(H1N1) vaccination coverage in Germany 2009/10 - results from thirteen consecutive cross-sectional surveys. Vaccine. 2011;29(23):4008-12.
6. von Kries R, Weiss S, Falkenhorst G, Wirth S, Kaiser P, Huppertz HI, et al. Post-Pandemic Seroprevalence of Pandemic Influenza A (H1N1) 2009 Infection (Swine Flu) among Children <18 Years in Germany. PLoS One. 2011;6(9):e23955.
7. European Centre for Disease Prevention and Control (ECDC). Understanding the Reproduction Number and Generation Times of Influenza A(H1N1) 2009. Stockholm: ECDC; 21 Aug 2009. Available from: http://www.ecdc.europa.eu/en/activities/sciadvice/Lists/ECDC%20Reviews/ECDC_DispForm.aspx?List=512ff74f%2D77d4%2D4ad8%2Db6d6%2Dbf0f23083f30&ID=641
8. Department of Health. Swine Flu. UK Planning Assumptions. London: Department of Health; 16 Jul 2009. Available from: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_102891.pdf
9. White LF, Wallinga J, Finelli L, Reed C, Riley S, Lipsitch M, et al. Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA. Influenza Other Respi Viruses. 2009;3(6):267-76.
10. Grassly NC, Fraser C. Mathematical models of infectious disease transmission. Nat Rev Microbiol. 2008;6(6):477-87.
11. Seroepidemiological studies of pandemic influenza A (H1N1) 2009 virus. Wkly Epidemiol Rec. 2010;85(24):229-35.
12. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375(9720):1100-8.
13. Bandaranayake D, Huang S, Bissielo A, Wood T. Seroprevalence of the 2009 influenza A (H1N1) pandemic in New Zealand. Wellington: Ministry of Health: May 2010. Available from: http://www.health.govt.nz/system/files/documents/publications/seroprevalence-flu-2009.pdf
14. Hardelid P, Andrews NJ, Hoschler K, Stanford E, Baguelin M, Waight PA, et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/ H1N1 2009. Health Technol Assess. 2010 Dec;14(55):115-92.
15. Allwinn R, Geiler J, Berger A, Cinatl J, Doerr HW. Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol. 2010;199(2):117-21.
16. Kissling E, Valenciano M, I-MOVE case-control studies team. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. Euro Surveill. 2011;16(11):pii=19818. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19818
17. Savulescu C, Jime´nez-Jorge S, de Mateo S, Ledesma J, Pozo F, Casas I, et al. Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case-control study. Euro Surveill. 2011;16(11).:pii=19820. Available from: http://www.eurosurveillance.org/ViewArticle. aspx?ArticleId=19820
18. Pebody R, Hardelid P, Fleming DM, McMenamin J, Andrews N, Robertson C, et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Euro Surveill. 2011;16(6):pii=19791. Available from: http://www.eurosurveillance.org/ViewArticle. aspx?ArticleId=19791
19. Puig-Barbera` J. 2010-2011 influenza seasonal vaccine, preliminary mid-season effectiveness estimates: reason for concern, confounding or are we following the right track? Euro Surveill. 2011;16(11):pii=19821. Available from: http://www. eurosurveillance.org/ViewArticle.aspx?ArticleId=19821
20. Ortqvist A. Challenges for implementation of the pandemic vaccination program: the Swedish experience. 1st International Conference on Controversies in Vaccination in Adults; 27-30 Jan 2011, Berlin, Germany.
21. Die soziale Situation in Deutschland. Bevo¨lkerungsentwicklung und Altersstruktur. [The social situation in Germany. Demographic development and age structure]. Bonn: Bundeszentrale fu¨r Politische Bildung. [Accessed 22 Sep 2011. Available from: http://www.bpb.de/wissen/1KNBKW,0,0,Bev%F6lkerungsentwicklung_und_Altersstruktur.html